shc-20220630
000182247912-31FALSE2022Q2P3YP1Y25000018224792022-01-012022-06-3000018224792022-07-27xbrli:shares00018224792022-06-30iso4217:USD00018224792021-12-31iso4217:USDxbrli:shares0001822479us-gaap:ServiceMember2022-04-012022-06-300001822479us-gaap:ServiceMember2021-04-012021-06-300001822479us-gaap:ServiceMember2022-01-012022-06-300001822479us-gaap:ServiceMember2021-01-012021-06-300001822479us-gaap:ProductMember2022-04-012022-06-300001822479us-gaap:ProductMember2021-04-012021-06-300001822479us-gaap:ProductMember2022-01-012022-06-300001822479us-gaap:ProductMember2021-01-012021-06-3000018224792022-04-012022-06-3000018224792021-04-012021-06-3000018224792021-01-012021-06-3000018224792020-12-3100018224792021-06-300001822479us-gaap:CommonStockMember2022-03-310001822479us-gaap:TreasuryStockMember2022-03-310001822479us-gaap:AdditionalPaidInCapitalMember2022-03-310001822479us-gaap:RetainedEarningsMember2022-03-310001822479us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001822479us-gaap:NoncontrollingInterestMember2022-03-3100018224792022-03-310001822479us-gaap:CommonStockMember2022-04-012022-06-300001822479us-gaap:TreasuryStockMember2022-04-012022-06-300001822479us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001822479us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001822479us-gaap:RetainedEarningsMember2022-04-012022-06-300001822479us-gaap:CommonStockMember2022-06-300001822479us-gaap:TreasuryStockMember2022-06-300001822479us-gaap:AdditionalPaidInCapitalMember2022-06-300001822479us-gaap:RetainedEarningsMember2022-06-300001822479us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001822479us-gaap:NoncontrollingInterestMember2022-06-300001822479us-gaap:CommonStockMember2021-12-310001822479us-gaap:TreasuryStockMember2021-12-310001822479us-gaap:AdditionalPaidInCapitalMember2021-12-310001822479us-gaap:RetainedEarningsMember2021-12-310001822479us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001822479us-gaap:NoncontrollingInterestMember2021-12-310001822479us-gaap:CommonStockMember2022-01-012022-06-300001822479us-gaap:TreasuryStockMember2022-01-012022-06-300001822479us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300001822479us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001822479us-gaap:RetainedEarningsMember2022-01-012022-06-300001822479us-gaap:CommonStockMember2021-03-310001822479us-gaap:TreasuryStockMember2021-03-310001822479us-gaap:AdditionalPaidInCapitalMember2021-03-310001822479us-gaap:RetainedEarningsMember2021-03-310001822479us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001822479us-gaap:NoncontrollingInterestMember2021-03-3100018224792021-03-310001822479us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001822479us-gaap:NoncontrollingInterestMember2021-04-012021-06-300001822479us-gaap:CommonStockMember2021-04-012021-06-300001822479us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001822479us-gaap:RetainedEarningsMember2021-04-012021-06-300001822479us-gaap:CommonStockMember2021-06-300001822479us-gaap:TreasuryStockMember2021-06-300001822479us-gaap:AdditionalPaidInCapitalMember2021-06-300001822479us-gaap:RetainedEarningsMember2021-06-300001822479us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001822479us-gaap:NoncontrollingInterestMember2021-06-300001822479us-gaap:CommonStockMember2020-12-310001822479us-gaap:TreasuryStockMember2020-12-310001822479us-gaap:AdditionalPaidInCapitalMember2020-12-310001822479us-gaap:RetainedEarningsMember2020-12-310001822479us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001822479us-gaap:NoncontrollingInterestMember2020-12-310001822479us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-300001822479us-gaap:NoncontrollingInterestMember2021-01-012021-06-300001822479us-gaap:CommonStockMember2021-01-012021-06-300001822479us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300001822479us-gaap:RetainedEarningsMember2021-01-012021-06-30shc:segment0001822479country:CNshc:SubsidiaryOneMember2021-04-012021-06-30xbrli:pure0001822479country:CNshc:SubsidiaryTwoMember2021-04-012021-06-300001822479country:CN2021-06-30shc:subsidiary0001822479shc:NelsonFairfieldIncNelsonFairfieldMember2021-03-112021-03-110001822479shc:UnnamedEBeamJointVentureMember2020-07-310001822479shc:AuraluxMember2022-06-300001822479shc:AuraluxMember2022-04-012022-06-300001822479shc:SterigenicsMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-06-300001822479shc:NordionMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-06-300001822479shc:NelsonLabsMemberus-gaap:TransferredAtPointInTimeMember2022-04-012022-06-300001822479us-gaap:TransferredAtPointInTimeMember2022-04-012022-06-300001822479us-gaap:TransferredOverTimeMembershc:SterigenicsMember2022-04-012022-06-300001822479us-gaap:TransferredOverTimeMembershc:NordionMember2022-04-012022-06-300001822479shc:NelsonLabsMemberus-gaap:TransferredOverTimeMember2022-04-012022-06-300001822479us-gaap:TransferredOverTimeMember2022-04-012022-06-300001822479shc:SterigenicsMember2022-04-012022-06-300001822479shc:NordionMember2022-04-012022-06-300001822479shc:NelsonLabsMember2022-04-012022-06-300001822479shc:SterigenicsMemberus-gaap:TransferredAtPointInTimeMember2021-04-012021-06-300001822479shc:NordionMemberus-gaap:TransferredAtPointInTimeMember2021-04-012021-06-300001822479shc:NelsonLabsMemberus-gaap:TransferredAtPointInTimeMember2021-04-012021-06-300001822479us-gaap:TransferredAtPointInTimeMember2021-04-012021-06-300001822479us-gaap:TransferredOverTimeMembershc:SterigenicsMember2021-04-012021-06-300001822479us-gaap:TransferredOverTimeMembershc:NordionMember2021-04-012021-06-300001822479shc:NelsonLabsMemberus-gaap:TransferredOverTimeMember2021-04-012021-06-300001822479us-gaap:TransferredOverTimeMember2021-04-012021-06-300001822479shc:SterigenicsMember2021-04-012021-06-300001822479shc:NordionMember2021-04-012021-06-300001822479shc:NelsonLabsMember2021-04-012021-06-300001822479shc:SterigenicsMemberus-gaap:TransferredAtPointInTimeMember2022-01-012022-06-300001822479shc:NordionMemberus-gaap:TransferredAtPointInTimeMember2022-01-012022-06-300001822479shc:NelsonLabsMemberus-gaap:TransferredAtPointInTimeMember2022-01-012022-06-300001822479us-gaap:TransferredAtPointInTimeMember2022-01-012022-06-300001822479us-gaap:TransferredOverTimeMembershc:SterigenicsMember2022-01-012022-06-300001822479us-gaap:TransferredOverTimeMembershc:NordionMember2022-01-012022-06-300001822479shc:NelsonLabsMemberus-gaap:TransferredOverTimeMember2022-01-012022-06-300001822479us-gaap:TransferredOverTimeMember2022-01-012022-06-300001822479shc:SterigenicsMember2022-01-012022-06-300001822479shc:NordionMember2022-01-012022-06-300001822479shc:NelsonLabsMember2022-01-012022-06-300001822479shc:SterigenicsMemberus-gaap:TransferredAtPointInTimeMember2021-01-012021-06-300001822479shc:NordionMemberus-gaap:TransferredAtPointInTimeMember2021-01-012021-06-300001822479shc:NelsonLabsMemberus-gaap:TransferredAtPointInTimeMember2021-01-012021-06-300001822479us-gaap:TransferredAtPointInTimeMember2021-01-012021-06-300001822479us-gaap:TransferredOverTimeMembershc:SterigenicsMember2021-01-012021-06-300001822479us-gaap:TransferredOverTimeMembershc:NordionMember2021-01-012021-06-300001822479shc:NelsonLabsMemberus-gaap:TransferredOverTimeMember2021-01-012021-06-300001822479us-gaap:TransferredOverTimeMember2021-01-012021-06-300001822479shc:SterigenicsMember2021-01-012021-06-300001822479shc:NordionMember2021-01-012021-06-300001822479shc:NelsonLabsMember2021-01-012021-06-300001822479shc:RegulatoryComplianceAssociatesIncRCAMember2021-11-042021-11-040001822479shc:RegulatoryComplianceAssociatesIncRCAMember2022-06-300001822479shc:RegulatoryComplianceAssociatesIncRCAMemberus-gaap:CustomerRelationshipsMember2022-06-300001822479country:CNshc:SubsidiaryOneMember2021-05-182021-05-180001822479country:CNshc:SubsidiaryTwoMember2021-05-182021-05-180001822479country:CN2021-05-180001822479shc:ChinaSubsidiariesMembercountry:CN2021-05-180001822479country:CN2021-05-182021-05-1800018224792021-05-182022-06-300001822479us-gaap:AdditionalPaidInCapitalMember2021-05-182022-06-300001822479shc:NelsonFairfieldIncNelsonFairfieldMember2021-03-110001822479shc:NelsonFairfieldIncNelsonFairfieldMember2021-03-112021-03-110001822479shc:NelsonFairfieldIncNelsonFairfieldMember2021-12-310001822479shc:NelsonFairfieldIncNelsonFairfieldMember2018-08-310001822479shc:BioScienceLaboratoriesLLCBioScienceMember2021-03-082021-03-080001822479shc:BioScienceLaboratoriesLLCBioScienceMember2021-03-080001822479shc:SterigenicsMember2021-12-310001822479shc:NordionMember2021-12-310001822479shc:NelsonLabsMember2021-12-310001822479shc:RegulatoryComplianceAssociatesIncRCAMembershc:SterigenicsMember2022-01-012022-06-300001822479shc:RegulatoryComplianceAssociatesIncRCAMembershc:NordionMember2022-01-012022-06-300001822479shc:RegulatoryComplianceAssociatesIncRCAMembershc:NelsonLabsMember2022-01-012022-06-300001822479shc:RegulatoryComplianceAssociatesIncRCAMember2022-01-012022-06-300001822479shc:SterigenicsMember2022-06-300001822479shc:NordionMember2022-06-300001822479shc:NelsonLabsMember2022-06-300001822479us-gaap:CustomerRelationshipsMember2022-06-300001822479us-gaap:DevelopedTechnologyRightsMember2022-06-300001822479us-gaap:TradeNamesMember2022-06-300001822479shc:LandUseRightsMember2022-06-300001822479shc:SealedSourceAndSupplyAgreementsMember2022-06-300001822479us-gaap:OtherIntangibleAssetsMember2022-06-300001822479us-gaap:LicensingAgreementsMember2022-06-300001822479us-gaap:TrademarksAndTradeNamesMember2022-06-300001822479us-gaap:CustomerRelationshipsMember2021-12-310001822479us-gaap:DevelopedTechnologyRightsMember2021-12-310001822479us-gaap:TradeNamesMember2021-12-310001822479shc:LandUseRightsMember2021-12-310001822479shc:SealedSourceAndSupplyAgreementsMember2021-12-310001822479us-gaap:OtherIntangibleAssetsMember2021-12-310001822479us-gaap:LicensingAgreementsMember2021-12-310001822479us-gaap:TrademarksAndTradeNamesMember2021-12-310001822479us-gaap:LicensingAgreementsMember2022-01-012022-06-300001822479us-gaap:OtherIntangibleAssetsMember2022-04-012022-06-300001822479us-gaap:OtherIntangibleAssetsMemberus-gaap:CostOfSalesMember2022-04-012022-06-300001822479us-gaap:OtherIntangibleAssetsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-04-012022-06-300001822479us-gaap:OtherIntangibleAssetsMember2022-01-012022-06-300001822479us-gaap:OtherIntangibleAssetsMemberus-gaap:CostOfSalesMember2022-01-012022-06-300001822479us-gaap:OtherIntangibleAssetsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-06-300001822479us-gaap:OtherIntangibleAssetsMember2021-04-012021-06-300001822479us-gaap:OtherIntangibleAssetsMemberus-gaap:CostOfSalesMember2021-04-012021-06-300001822479us-gaap:OtherIntangibleAssetsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-04-012021-06-300001822479us-gaap:OtherIntangibleAssetsMember2021-01-012021-06-300001822479us-gaap:OtherIntangibleAssetsMemberus-gaap:CostOfSalesMember2021-01-012021-06-300001822479us-gaap:OtherIntangibleAssetsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-06-300001822479shc:TermLoanDue2026Membershc:TermLoanMember2022-06-300001822479shc:TermLoanDue2026Membershc:TermLoanMember2021-12-310001822479shc:OtherLongTermDebtMember2022-06-300001822479shc:OtherLongTermDebtMember2021-12-310001822479shc:SeniorSecuredCreditFacilitiesMemberus-gaap:RevolvingCreditFacilityMember2019-12-130001822479shc:SeniorSecuredCreditFacilitiesMemberus-gaap:RevolvingCreditFacilityMember2021-12-310001822479shc:TermLoanDue2026Membershc:TermLoanMember2022-04-012022-06-300001822479shc:TermLoanDue2026Membershc:TermLoanMember2021-04-012021-06-300001822479shc:TermLoanDue2026Membershc:TermLoanMember2022-01-012022-06-300001822479shc:TermLoanDue2026Membershc:TermLoanMember2021-01-012021-06-300001822479shc:TermLoanDue2026Memberus-gaap:LondonInterbankOfferedRateLIBORMembershc:TermLoanMember2021-01-192021-01-190001822479shc:TermLoanDue2026Memberus-gaap:LondonInterbankOfferedRateLIBORMembershc:TermLoanMember2021-01-202021-01-200001822479shc:TermLoanDue2026Memberus-gaap:LondonInterbankOfferedRateLIBORMembershc:TermLoanMember2021-01-190001822479shc:TermLoanDue2026Memberus-gaap:LondonInterbankOfferedRateLIBORMembershc:TermLoanMember2021-01-200001822479shc:TermLoanDue2026Membershc:TermLoanMember2021-01-200001822479srt:MinimumMembershc:SeniorSecuredCreditFacilitiesMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMember2021-03-262021-03-260001822479shc:SeniorSecuredCreditFacilitiesMemberus-gaap:BaseRateMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2021-03-262021-03-260001822479shc:FirstLienNotesDue2026Memberus-gaap:BaseRateMemberus-gaap:SecuredDebtMember2021-03-262021-03-260001822479shc:FirstLienNotesDue2026Membersrt:MinimumMemberus-gaap:SecuredDebtMemberus-gaap:EurodollarMember2021-03-262021-03-260001822479shc:FirstLienNotesDue2026Membersrt:MaximumMemberus-gaap:SecuredDebtMemberus-gaap:EurodollarMember2021-03-262021-03-260001822479shc:FirstLienNotesDue2026Memberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:SecuredDebtMember2021-03-262021-03-260001822479shc:SeniorSecuredCreditFacilitiesMembershc:TermLoanMember2022-06-300001822479shc:SeniorSecuredCreditFacilitiesMembershc:TermLoanMember2021-12-310001822479shc:SeniorSecuredCreditFacilitiesMemberus-gaap:RevolvingCreditFacilityMember2022-06-300001822479shc:FirstLienNotesDue2026Memberus-gaap:SecuredDebtMember2020-07-310001822479shc:FirstLienNotesDue2026Memberus-gaap:SecuredDebtMember2020-07-312020-07-310001822479shc:FirstLienNotesDue2026Memberus-gaap:LondonInterbankOfferedRateLIBORMemberus-gaap:SecuredDebtMember2022-01-012022-06-300001822479shc:FirstLienNotesDue2026Memberus-gaap:SecuredDebtMember2022-01-012022-06-300001822479us-gaap:PensionPlansDefinedBenefitMember2022-04-012022-06-300001822479us-gaap:PensionPlansDefinedBenefitMember2021-04-012021-06-300001822479us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-06-300001822479us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-06-300001822479us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-04-012022-06-300001822479us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-04-012021-06-300001822479us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-06-300001822479us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-06-300001822479us-gaap:PensionPlansDefinedBenefitMembersrt:MaximumMember2022-01-012022-06-300001822479us-gaap:PensionPlansDefinedBenefitMember2022-06-300001822479us-gaap:PensionPlansDefinedBenefitMember2021-12-310001822479us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-03-310001822479us-gaap:AccumulatedTranslationAdjustmentMember2022-03-310001822479us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-03-310001822479us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-04-012022-06-300001822479us-gaap:AccumulatedTranslationAdjustmentMember2022-04-012022-06-300001822479us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-04-012022-06-300001822479us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-06-300001822479us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300001822479us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-06-300001822479us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310001822479us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001822479us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-12-310001822479us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-06-300001822479us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-06-300001822479us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-01-012022-06-300001822479us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-03-310001822479us-gaap:AccumulatedTranslationAdjustmentMember2021-03-310001822479us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-03-310001822479us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-04-012021-06-300001822479us-gaap:AccumulatedTranslationAdjustmentMember2021-04-012021-06-300001822479us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-04-012021-06-300001822479us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-06-300001822479us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300001822479us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-06-300001822479us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310001822479us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001822479us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-12-310001822479us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-06-300001822479us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-06-300001822479us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-01-012021-06-300001822479shc:PreIPOB1Memberus-gaap:RestrictedStockMember2022-01-012022-06-300001822479us-gaap:ShareBasedCompensationAwardTrancheTwoMembershc:PreIPOB1Memberus-gaap:RestrictedStockMember2022-01-012022-06-300001822479shc:ShareBasedPaymentArrangementTrancheFiveMembershc:PreIPOB1Memberus-gaap:RestrictedStockMember2022-01-012022-06-300001822479shc:PreIPOB1Memberus-gaap:RestrictedStockMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2022-01-012022-06-300001822479shc:PreIPOB1Memberus-gaap:RestrictedStockMembershc:ShareBasedPaymentArrangementTrancheFourMember2022-01-012022-06-300001822479us-gaap:ShareBasedCompensationAwardTrancheOneMembershc:PreIPOB1Memberus-gaap:RestrictedStockMember2022-01-012022-06-300001822479shc:PreIPOB2Membersrt:MinimumMemberus-gaap:RestrictedStockMember2022-01-012022-06-300001822479shc:PreIPOB1Memberus-gaap:RestrictedStockMember2022-04-012022-06-300001822479shc:PreIPOB1Memberus-gaap:RestrictedStockMember2021-04-012021-06-300001822479shc:PreIPOB1Memberus-gaap:RestrictedStockMember2021-01-012021-06-300001822479shc:PreIPOB1Memberus-gaap:RestrictedStockMember2021-12-310001822479shc:PreIPOB2Memberus-gaap:RestrictedStockMember2021-12-310001822479shc:PreIPOB2Memberus-gaap:RestrictedStockMember2022-01-012022-06-300001822479shc:PreIPOB1Memberus-gaap:RestrictedStockMember2022-06-300001822479shc:PreIPOB2Memberus-gaap:RestrictedStockMember2022-06-300001822479shc:A2020OmnibusIncentivePlanMember2022-04-012022-06-300001822479us-gaap:EmployeeStockOptionMembershc:A2020OmnibusIncentivePlanMember2022-04-012022-06-300001822479us-gaap:RestrictedStockUnitsRSUMembershc:A2020OmnibusIncentivePlanMember2022-04-012022-06-300001822479shc:A2020OmnibusIncentivePlanMember2021-04-012021-06-300001822479us-gaap:EmployeeStockOptionMembershc:A2020OmnibusIncentivePlanMember2021-04-012021-06-300001822479us-gaap:RestrictedStockUnitsRSUMembershc:A2020OmnibusIncentivePlanMember2021-04-012021-06-300001822479shc:A2020OmnibusIncentivePlanMember2022-01-012022-06-300001822479us-gaap:EmployeeStockOptionMembershc:A2020OmnibusIncentivePlanMember2022-01-012022-06-300001822479us-gaap:RestrictedStockUnitsRSUMembershc:A2020OmnibusIncentivePlanMember2022-01-012022-06-300001822479shc:A2020OmnibusIncentivePlanMember2021-01-012021-06-300001822479us-gaap:EmployeeStockOptionMembershc:A2020OmnibusIncentivePlanMember2021-01-012021-06-300001822479us-gaap:RestrictedStockUnitsRSUMembershc:A2020OmnibusIncentivePlanMember2021-01-012021-06-300001822479us-gaap:EmployeeStockOptionMembersrt:MinimumMember2022-01-012022-06-300001822479us-gaap:EmployeeStockOptionMembersrt:MaximumMember2022-01-012022-06-300001822479us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001822479us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2022-01-012022-06-300001822479us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2022-01-012022-06-300001822479us-gaap:RestrictedStockUnitsRSUMember2021-12-310001822479us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001822479us-gaap:RestrictedStockUnitsRSUMember2022-06-300001822479us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001822479us-gaap:EmployeeStockOptionMember2021-04-012021-06-300001822479us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001822479us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300001822479us-gaap:RestrictedStockUnitsRSUMember2021-04-012021-06-300001822479us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300001822479shc:EthyleneOxideTortLitigationIllinoisMemberus-gaap:PendingLitigationMember2018-09-012021-03-31shc:plaintiff0001822479us-gaap:PendingLitigationMembershc:EthyleneOxideTortLitigationGeorgiaMember2020-08-172020-08-170001822479us-gaap:PendingLitigationMembershc:EthyleneOxideTortLitigationGeorgiaMember2022-01-012022-06-300001822479us-gaap:PendingLitigationMembershc:EthyleneOxideTortLitigationGeorgiaMember2022-06-300001822479us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateCapMember2022-05-31shc:instrument0001822479us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateCapMember2021-10-310001822479us-gaap:NondesignatedMembershc:InterestRateCapJune2020Member2020-06-300001822479us-gaap:NondesignatedMemberus-gaap:InterestRateCapMember2020-06-300001822479us-gaap:NondesignatedMemberus-gaap:InterestRateSwapMember2020-06-300001822479us-gaap:NondesignatedMemberus-gaap:InterestRateCapMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-06-300001822479shc:InterestRateCapFebruary2021Memberus-gaap:NondesignatedMember2021-02-280001822479us-gaap:NondesignatedMemberus-gaap:InterestRateCapMember2021-02-280001822479us-gaap:ForeignExchangeContractMember2021-12-310001822479us-gaap:ForeignExchangeContractMember2022-06-300001822479us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateCapMember2022-06-300001822479us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateCapMember2021-12-310001822479us-gaap:NondesignatedMemberus-gaap:InterestRateCapMember2022-06-300001822479us-gaap:NondesignatedMemberus-gaap:InterestRateCapMember2021-12-310001822479us-gaap:NondesignatedMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMember2022-06-300001822479us-gaap:NondesignatedMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMember2021-12-310001822479us-gaap:NondesignatedMember2022-06-300001822479us-gaap:NondesignatedMember2021-12-310001822479us-gaap:InterestRateCapMember2022-04-012022-06-300001822479us-gaap:InterestRateCapMember2021-04-012021-06-300001822479us-gaap:InterestRateCapMember2022-01-012022-06-300001822479us-gaap:InterestRateCapMember2021-01-012021-06-300001822479us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2022-04-012022-06-300001822479us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2021-04-012021-06-300001822479us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2022-01-012022-06-300001822479us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2021-01-012021-06-300001822479us-gaap:ForeignExchangeContractMember2022-04-012022-06-300001822479us-gaap:ForeignExchangeContractMember2021-04-012021-06-300001822479us-gaap:ForeignExchangeContractMember2022-01-012022-06-300001822479us-gaap:ForeignExchangeContractMember2021-01-012021-06-300001822479us-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-06-300001822479us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateCapMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-06-300001822479us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel1Member2022-06-300001822479us-gaap:FairValueInputsLevel2Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateCapMember2022-06-300001822479us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel3Member2022-06-300001822479us-gaap:NondesignatedMemberus-gaap:InterestRateCapMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-06-300001822479us-gaap:NondesignatedMemberus-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel1Member2022-06-300001822479us-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateCapMember2022-06-300001822479us-gaap:NondesignatedMemberus-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel3Member2022-06-300001822479us-gaap:NondesignatedMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-06-300001822479us-gaap:NondesignatedMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel1Member2022-06-300001822479us-gaap:NondesignatedMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel2Member2022-06-300001822479us-gaap:NondesignatedMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel3Member2022-06-300001822479shc:TermLoanDue2026Memberus-gaap:NondesignatedMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-06-300001822479shc:TermLoanDue2026Memberus-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel1Member2022-06-300001822479shc:TermLoanDue2026Memberus-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel2Member2022-06-300001822479shc:TermLoanDue2026Memberus-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel3Member2022-06-300001822479us-gaap:NondesignatedMembershc:OtherLongTermDebtMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-06-300001822479us-gaap:NondesignatedMembershc:OtherLongTermDebtMemberus-gaap:FairValueInputsLevel1Member2022-06-300001822479us-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel2Membershc:OtherLongTermDebtMember2022-06-300001822479us-gaap:NondesignatedMembershc:OtherLongTermDebtMemberus-gaap:FairValueInputsLevel3Member2022-06-300001822479us-gaap:NondesignatedMemberus-gaap:CarryingReportedAmountFairValueDisclosureMembershc:FinanceLeaseLiabilityMember2022-06-300001822479us-gaap:NondesignatedMembershc:FinanceLeaseLiabilityMemberus-gaap:FairValueInputsLevel1Member2022-06-300001822479us-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel2Membershc:FinanceLeaseLiabilityMember2022-06-300001822479us-gaap:NondesignatedMembershc:FinanceLeaseLiabilityMemberus-gaap:FairValueInputsLevel3Member2022-06-300001822479us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateCapMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001822479us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel1Member2021-12-310001822479us-gaap:FairValueInputsLevel2Memberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateCapMember2021-12-310001822479us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel3Member2021-12-310001822479us-gaap:NondesignatedMemberus-gaap:InterestRateCapMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001822479us-gaap:NondesignatedMemberus-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel1Member2021-12-310001822479us-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateCapMember2021-12-310001822479us-gaap:NondesignatedMemberus-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel3Member2021-12-310001822479us-gaap:NondesignatedMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001822479us-gaap:NondesignatedMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel1Member2021-12-310001822479us-gaap:NondesignatedMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel2Member2021-12-310001822479us-gaap:NondesignatedMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueInputsLevel3Member2021-12-310001822479shc:TermLoanDue2026Memberus-gaap:NondesignatedMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001822479shc:TermLoanDue2026Memberus-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel1Member2021-12-310001822479shc:TermLoanDue2026Memberus-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel2Member2021-12-310001822479shc:TermLoanDue2026Memberus-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel3Member2021-12-310001822479us-gaap:NondesignatedMembershc:OtherLongTermDebtMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310001822479us-gaap:NondesignatedMembershc:OtherLongTermDebtMemberus-gaap:FairValueInputsLevel1Member2021-12-310001822479us-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel2Membershc:OtherLongTermDebtMember2021-12-310001822479us-gaap:NondesignatedMembershc:OtherLongTermDebtMemberus-gaap:FairValueInputsLevel3Member2021-12-310001822479us-gaap:NondesignatedMemberus-gaap:CarryingReportedAmountFairValueDisclosureMembershc:FinanceLeaseLiabilityMember2021-12-310001822479us-gaap:NondesignatedMembershc:FinanceLeaseLiabilityMemberus-gaap:FairValueInputsLevel1Member2021-12-310001822479us-gaap:NondesignatedMemberus-gaap:FairValueInputsLevel2Membershc:FinanceLeaseLiabilityMember2021-12-310001822479us-gaap:NondesignatedMembershc:FinanceLeaseLiabilityMemberus-gaap:FairValueInputsLevel3Member2021-12-310001822479us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembershc:NordionMembershc:CustomerOneMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300001822479shc:CustomerTwoMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembershc:NordionMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300001822479shc:CustomerThreeMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembershc:NordionMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300001822479us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembershc:NordionMemberus-gaap:OperatingSegmentsMembershc:CustomerFourMember2022-04-012022-06-300001822479us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembershc:NordionMembershc:CustomerOneMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300001822479shc:CustomerTwoMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembershc:NordionMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300001822479us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembershc:NordionMembershc:CustomerOneMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300001822479shc:CustomerTwoMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembershc:NordionMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300001822479shc:CustomerThreeMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembershc:NordionMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300001822479us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembershc:NordionMemberus-gaap:OperatingSegmentsMembershc:CustomerFourMember2022-01-012022-06-300001822479us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembershc:NordionMembershc:CustomerOneMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300001822479shc:CustomerTwoMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembershc:NordionMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300001822479shc:CustomerThreeMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembershc:NordionMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300001822479us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMembershc:NordionMemberus-gaap:OperatingSegmentsMembershc:CustomerFourMember2021-01-012021-06-300001822479shc:SterigenicsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300001822479shc:SterigenicsMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300001822479shc:SterigenicsMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300001822479shc:SterigenicsMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300001822479shc:NordionMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300001822479shc:NordionMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300001822479shc:NordionMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300001822479shc:NordionMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300001822479shc:NelsonLabsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300001822479shc:NelsonLabsMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300001822479shc:NelsonLabsMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300001822479shc:NelsonLabsMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300001822479us-gaap:OperatingSegmentsMember2022-04-012022-06-300001822479us-gaap:OperatingSegmentsMember2021-04-012021-06-300001822479us-gaap:OperatingSegmentsMember2022-01-012022-06-300001822479us-gaap:OperatingSegmentsMember2021-01-012021-06-300001822479us-gaap:IntersegmentEliminationMember2022-04-012022-06-300001822479us-gaap:IntersegmentEliminationMember2021-04-012021-06-300001822479us-gaap:IntersegmentEliminationMember2022-01-012022-06-300001822479us-gaap:IntersegmentEliminationMember2021-01-012021-06-300001822479us-gaap:MaterialReconcilingItemsMember2022-04-012022-06-300001822479us-gaap:MaterialReconcilingItemsMember2021-04-012021-06-300001822479us-gaap:MaterialReconcilingItemsMember2022-01-012022-06-300001822479us-gaap:MaterialReconcilingItemsMember2021-01-012021-06-300001822479us-gaap:InterestExpenseMemberus-gaap:InterestRateCapMember2022-04-012022-06-300001822479us-gaap:InterestExpenseMemberus-gaap:InterestRateCapMember2022-01-012022-06-30
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2022
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to
Commission file number   001-39729
https://cdn.kscope.io/54fa99b41a791beeee0ad46d9b326fde-shc-20220630_g1.jpg
SOTERA HEALTH COMPANY
(Exact name of registrant as specified in its charter)
Delaware47-3531161
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
9100 South Hills Blvd, Suite 300
Broadview Heights, Ohio
44147
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code
(440)
262-1410
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par value per shareSHCThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes   No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes   No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes    No
As of July 27, 2022, there were 282,902,367 shares of the registrant’s common stock, $0.01 par value per share, outstanding.


Table of Contents
SOTERA HEALTH COMPANY
- TABLE OF CONTENTS -


Table of Contents
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements are often characterized by the use of the words such as “believes,” “estimates,” “expects,” “projects,” “may,” “intends,” “plans” or “anticipates,” or by discussions of strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from historical results or any future results, performance or achievements expressed, suggested or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to:
disruption in the availability of, or increases in the price of, ethylene oxide (“EO”), Cobalt-60 (“Co-60”) or our other direct materials, services and supplies, including as a result of current geopolitical instability arising from U.S., Canadian and European Union relations with Russia and related sanctions;
adverse changes in industry trends;
changes in environmental, health and safety regulations or preferences;
health and safety risks associated with the use, storage, transportation and disposal of potentially hazardous materials such as EO and Co-60;
liability claims relating to health risks associated with the use of EO;
current and future legal proceedings;
competition we face;
market changes, including inflationary trends, that impact our long-term supply contracts with variable price clauses and increase our cost of revenues;
allegations of our failure to properly perform services and potential product liability claims, recalls, penalties and reputational harm;
compliance with the extensive regulatory requirements to which we are subject, the related costs, and any failures to receive or maintain, or delays in receiving, required clearance or approvals;
business continuity hazards, including supply chain disruptions and other risks associated with our operations;
the ongoing impact of the COVID-19 pandemic;
our ability to increase capacity at existing facilities, build new facilities in a timely and cost-effective manner and renew leases for our facilities;
our ability to attract and retain qualified employees;
the risks of doing business internationally, including global and regional economic and political instability and compliance with numerous laws and regulations in multiple jurisdictions;
cyber security breaches, unauthorized data disclosures, and our dependence on information technology systems;
any inability to pursue strategic transactions, including our ability to find suitable acquisition targets, or our failure to integrate strategic acquisitions successfully into our business;
our ability to maintain effective internal controls over financial reporting;
our reliance on intellectual property to maintain our competitive position and the risk of claims from third parties that we infringe or misappropriate their intellectual property rights;
our ability to comply with rapidly evolving data privacy and security laws and regulations and any ineffective compliance efforts with such laws and regulations;
the effects of unionization efforts and labor regulations in certain countries in which we operate;
our ability to maintain profitability in the future;
impairment charges on our goodwill and other intangible assets with indefinite lives, as well as other long-lived assets and intangible assets with definite lives;
adverse changes to our tax positions in U.S. or non-U.S. jurisdictions, the interpretation and application of recent U.S. tax legislation or other changes in U.S. or non-U.S. taxation of our operations;
our significant leverage could adversely affect our ability to raise additional capital, limit our ability to react to changes in the economy or our industry, limit our flexibility in operating our business through restrictions contained in our debt agreements and prevent us from meeting our obligations under our existing and future indebtedness; and
uncertainty around discontinuation of LIBOR and transition to certain other interest “benchmarks.”
These statements are based on current plans, estimates and projections, and therefore you should not place undue reliance on them. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them publicly in light of new information or future events, except as required by law. The inclusion of this forward-looking information should not be regarded as a representation by us or any other person that the future plans, estimates or expectations contemplated by us will be achieved.
3

Table of Contents
You should carefully consider the above factors, as well as the factors discussed elsewhere in this Quarterly Report on Form 10-Q, including under Part II, Item 1A, “Risk Factors,” as well as Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 10-K”). If any of these trends, risks or uncertainties actually occurs or continues, our business, financial condition or operating results could be materially adversely affected, the trading prices of our securities could decline and you could lose all or part of your investment. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.
Unless expressly indicated or the context requires otherwise, the terms “Sotera Health,” “Company,” “we,” “us,” and “our” in this document refer to Sotera Health Company, a Delaware corporation, and, where appropriate, its subsidiaries on a consolidated basis.
4

Table of Contents
Part I—FINANCIAL INFORMATION
Item 1. Financial Statements
Sotera Health Company
Consolidated Balance Sheets
(in thousands)
As of
June 30, 2022December 31, 2021
Assets(Unaudited)
Current assets:
Cash and cash equivalents$139,564 $106,917 
Restricted cash short-term1,054 7 
Accounts receivable, net of allowance for uncollectible accounts of $1,816 and $1,287, respectively
119,852 108,183 
Inventories, net39,652 54,288 
Prepaid expenses and other current assets81,173 71,923 
Income taxes receivable17,386 4,643 
Total current assets398,681 345,961 
Property, plant, and equipment, net699,571 650,797 
Operating lease assets29,853 39,946 
Deferred income taxes5,425 5,885 
Investment in unconsolidated affiliate 9,405 
Post-retirement assets8,788 5,478 
Other assets38,308 12,866 
Other intangible assets, net543,057 598,844 
Goodwill1,116,002 1,120,320 
Total assets$2,839,685 $2,789,502 
Liabilities and equity
Current liabilities:
Accounts payable$65,271 $72,868 
Accrued liabilities52,658 61,861 
Deferred revenues6,863 8,669 
Current portion of finance lease obligations1,615 1,160 
Current portion of operating lease obligations8,132 9,289 
Current portion of asset retirement obligations606 619 
Income taxes payable6,876 6,695 
Total current liabilities142,021 161,161 
Long-term debt1,745,548 1,743,534 
Finance lease obligations, less current portion57,140 40,877 
Operating lease obligations, less current portion24,546 33,017 
Noncurrent asset retirement obligations42,688 41,833 
Deferred lease income20,146 20,745 
Post-retirement obligations11,198 11,464 
Noncurrent liabilities15,668 16,274 
Deferred income taxes144,730 134,501 
Total liabilities2,203,685 2,203,406 
See Commitments and contingencies note
Equity:
Common stock, with $0.01 par value, 1,200,000 shares authorized; 286,037 shares issued at June 30, 2022 and December 31, 2021, respectively.
2,860 2,860 
Preferred stock, with $0.01 par value, 120,000 authorized; no shares issued at June 30, 2022 and
December 31, 2021, respectively
  
Treasury stock, at cost (3,135 and 3,052 shares at June 30, 2022 and December 31, 2021, respectively)
(32,654)(33,545)
Additional paid-in capital1,181,995 1,172,593 
Retained deficit(411,187)(472,246)
Accumulated other comprehensive loss(105,014)(83,566)
Total equity attributable to Sotera Health Company636,000 586,096 
Noncontrolling interests  
Total equity636,000 586,096 
Total liabilities and equity$2,839,685 $2,789,502 
See notes to consolidated financial statements.
5

Table of Contents
Sotera Health Company
Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except per share amounts)
(Unaudited)
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Revenues:
Service$221,529 $208,710 $427,747 $397,408 
Product45,110 43,207 75,646 66,657 
Total net revenues266,639 251,917 503,393 464,065 
Cost of revenues:
Service98,407 91,391 192,983 176,427 
Product17,836 16,765 31,139 28,505 
Total cost of revenues116,243 108,156 224,122 204,932 
Gross profit150,396 143,761 279,271 259,133 
Operating expenses:
Selling, general and administrative expenses63,132 49,828 122,674 102,293 
Amortization of intangible assets15,769 15,661 31,610 32,204 
Total operating expenses78,901 65,489 154,284 134,497 
Operating income71,495 78,272 124,987 124,636 
Interest expense, net14,044 19,163 24,448 40,445 
Impairment of investment in unconsolidated affiliate9,613  9,613  
Loss on extinguishment of debt   14,312 
Foreign exchange (gain) loss (755)76 33 654 
Other expense (income), net485 (2,764)(2,482)(6,654)
Income before income taxes48,108 61,797 93,375 75,879 
Provision for income taxes17,690 19,182 32,316 22,199 
Net income30,418 42,615 61,059 53,680 
Less: Net income attributable to noncontrolling interests 16  239 
Net income attributable to Sotera Health Company30,418 42,599 61,059 53,441 
Other comprehensive income (loss) net of tax:
Pension and post-retirement benefits (net of taxes of $179, $(142), $87, and $(226), respectively)
532 (421)258 (670)
Interest rate derivatives (net of taxes of $1,241, $0, $3,350 and $0, respectively)
3,178  9,357  
Foreign currency translation(46,038)20,425 (31,063)17,339 
Comprehensive income (loss)(11,910)62,619 39,611 70,349 
Less: comprehensive income attributable to noncontrolling interests 326  534 
Comprehensive income (loss) attributable to Sotera Health Company$(11,910)$62,293 $39,611 $69,815 
Earnings per share:
Basic$0.11 $0.15 $0.22 $0.19 
Diluted0.11 0.15 0.22 0.19 
Weighted average number of shares outstanding:
Basic279,990 279,078 279,910 278,953 
Diluted280,171 279,214 280,038 279,078 
See notes to consolidated financial statements.
6

Table of Contents
Sotera Health Company
Consolidated Statements of Cash Flows
(in thousands)
(Unaudited)
Six Months Ended June 30,
20222021
Operating activities:
Net income$61,059 $53,680 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation31,611 31,062 
Amortization of intangible assets41,378 44,060 
Impairment of investment in unconsolidated affiliate9,613  
Loss on extinguishment of debt 14,312 
Deferred income taxes10,416 3,504 
Share-based compensation expense10,339 6,942 
Accretion of asset retirement obligations1,118 1,153 
Unrealized foreign exchange losses1,274 1,097 
Unrealized gains on derivatives not designated as hedging instruments(8,029)(1,614)
Amortization of debt issuance costs2,836 3,245 
Other(4,043)(4,241)
Changes in operating assets and liabilities:
Accounts receivable(13,921)(25,754)
Inventories14,012 (770)
Other current assets(6,683)983 
Accounts payable(9,993)15,080 
Accrued liabilities(11,869)(4,375)
Income taxes payable / receivable(15,968)(3,998)
Other liabilities(468)(95)
Other long-term assets(4,426)(15)
Net cash provided by operating activities108,256 134,256 
Investing activities:
Purchases of property, plant and equipment(71,642)(44,789)
Purchase of mandatorily redeemable noncontrolling interest in Nelson Laboratories Fairfield, Inc. (12,425)
Purchase of BioScience Laboratories, LLC, net of cash acquired (13,760)
Adjustment to purchase of Regulatory Compliance Associates Inc.450 
Net cash used in investing activities(71,192)(70,974)
Financing activities:
Purchase of noncontrolling interests in China subsidiaries (7,720)
Payments of debt issuance costs(27)(3,661)
Other financing activities(1,056)(709)
Net cash used in financing activities(1,083)(12,090)
Effect of exchange rate changes on cash and cash equivalents(2,287)2,578 
Net increase in cash and cash equivalents, including restricted cash33,694 53,770 
Cash and cash equivalents, including restricted cash, at beginning of period106,924 102,454 
Cash and cash equivalents, including restricted cash, at end of period$140,618 $156,224 
Supplemental disclosures of cash flow information:
Cash paid during the period for interest$42,057 $36,615 
Cash paid during the period for income taxes, net of tax refunds received37,340 22,785 
Purchases of property, plant and equipment included in accounts payable17,923 9,670 
See notes to consolidated financial statements.
7

Table of Contents
Sotera Health Company
Consolidated Statements of Equity
(in thousands)
(Unaudited)
Three Months Ended June 30, 2022
Common Stock
Additional
Paid-In
Capital
Retained
Earnings /
(Accumulated
Deficit)
Accumulated
Other
Comprehensive
(Loss) Income
Noncontrolling
Interests
Total
Equity
Shares
Amount
Treasury
Stock
Balance at March 31, 2022282,930 $2,860 $(33,536)$1,177,097 $(441,605)$(62,686)$ $642,130 
Share-based compensation plans(28)— 882 4,898 — — — 5,780 
Comprehensive income (loss):
Pension and post-retirement plan adjustments, net of tax— — — — — 532 — 532 
Foreign currency translation— — — — — (46,038)— (46,038)
Interest rate derivatives, net of tax— — — — — 3,178 — 3,178 
Net income — — — — 30,418 — — 30,418
Balance at June 30, 2022282,902 $2,860 $(32,654)$1,181,995 $(411,187)$(105,014)$ $636,000 
Six Months Ended June 30, 2022
Common Stock

Additional
Paid-In
Capital
Retained
Earnings /
(Accumulated
Deficit)
Accumulated
Other
Comprehensive
(Loss) Income
Noncontrolling
Interests
Total
Equity
Shares
Amount
Treasury
Stock
Balance at December 31, 2021282,985 $2,860 $(33,545)$1,172,593 $(472,246)$(83,566)$ $586,096 
Share-based compensation plans(83)— 891 9,402 — — — 10,293 
Comprehensive income (loss):
Pension and post-retirement plan adjustments, net of tax— — — — — 258 — 258 
Foreign currency translation— — — — — (31,063)— (31,063)
Interest rate derivatives, net of tax— — — — — 9,357 — 9,357 
Net income— — — — 61,059 — — 61,059
Balance at June 30, 2022282,902 $2,860 $(32,654)$1,181,995 $(411,187)$(105,014)$ $636,000 
See notes to consolidated financial statements.
8

Table of Contents
Sotera Health Company
Consolidated Statements of Equity (continued)
(in thousands)
(Unaudited)
Three Months Ended June 30, 2021
Common Stock

Additional
Paid-In
Capital
Retained
Earnings /
(Accumulated
Deficit)
Accumulated
Other
Comprehensive
(Loss) Income
Noncontrolling
Interests
Total
Equity
Shares
Amount
Treasury
Stock
Balance at March 31, 2021282,900 $2,860 $(34,000)$1,169,852 $(578,286)$(97,162)$2,480 $465,744 
Acquisition of noncontrolling interests— — — (5,772)— — (2,806)(8,578)
Issuance of shares47 — — 1,080 — — — 1,080 
Share-based compensation plans(30)— — 2,406 — — — 2,406 
Comprehensive income (loss):
Pension and post-retirement plan adjustments, net of tax— — — — — (421)— (421)
Foreign currency translation— — — — — 20,115 310 20,425 
Net income— — — — 42,599 — 16 42,615 
Balance at June 30, 2021282,917 $2,860 $(34,000)$1,167,566 $(535,687)$(77,468)$ $523,271 
Six Months Ended June 30, 2021
Common Stock

Additional
Paid-In
Capital
Retained
Earnings /
(Accumulated
Deficit)
Accumulated
Other
Comprehensive
(Loss) Income
Noncontrolling
Interests
Total
Equity
Shares
Amount
Treasury
Stock
Balance at December 31, 2020283,248 $2,860 $(34,000)$1,166,412 $(589,128)$(93,842)$2,272 $454,574 
Acquisition of noncontrolling interests— — — (5,772)— — (2,806)(8,578)
Issuance of shares47 — — 1,080 — — — 1,080 
Share-based compensation plans(378)— — 5,846 — — — 5,846 
Comprehensive income (loss):
Pension and post-retirement plan adjustments, net of tax— — — — — (670)— (670)
Foreign currency translation— — — — — 17,044 295 17,339 
Net income— — — — 53,441 — 239 53,680
Balance at June 30, 2021282,917 $2,860 $(34,000)$1,167,566 $(535,687)$(77,468)$ $523,271 
See notes to consolidated financial statements.
9

Table of Contents
Sotera Health Company
Notes to Consolidated Financial Statements

1.Basis of Presentation
Principles of Consolidation – Sotera Health Company (also referred to herein as the “Company,” “we,” “our,” “us” or “its”), is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry with operations primarily in the Americas, Europe and Asia.
We operate and report in three segments, Sterigenics, Nordion and Nelson Labs. We describe our reportable segments in Note 18, “Segment Information”. All significant intercompany balances and transactions have been eliminated in consolidation.
Noncontrolling interests represented the noncontrolling stockholders’ proportionate share of the total equity in the Company’s consolidated subsidiaries. In the second quarter of 2021, we purchased the outstanding noncontrolling interests of 15% and 33% of our two China subsidiaries. Refer to Note 4, “Acquisitions” for additional details. Prior to our acquisition of the noncontrolling interests in our two subsidiaries in China, we consolidated the results of operations of these subsidiaries with our results of operations and reflected the noncontrolling interest on our Consolidated Statements of Operations and Comprehensive Income (Loss) as “Net income attributable to noncontrolling interests.”
On March 11, 2021, we purchased the 15% noncontrolling interest that remained from the August 2018 acquisition of Nelson Laboratories Fairfield, Inc. (“Nelson Labs Fairfield”). As the purchase of this noncontrolling interest was mandatorily redeemable, no earnings were allocated to this noncontrolling interest. See Note 4, “Acquisitions” for additional details.
In July 2020, we acquired a 60% equity ownership interest in Auralux Enterprises, Ltd. (“Auralux”), a joint venture to construct an E-beam facility in Alberta, Canada in connection with our acquisition of Iotron Industries Canada, Inc. (“Iotron”). We determined this to be an investment in a variable interest entity (“VIE”). The investment was not consolidated as the Company concluded that we are not the primary beneficiary of the VIE. The Company accounts for the joint venture using the equity method. The investment is reflected within “Investment in unconsolidated affiliates” on the Consolidated Balance Sheets. During the three months ended June 30, 2022, we identified certain events and circumstances that indicated a decline in value of our investment in Auralux that was other-than-temporary. Consequently, as of June 30, 2022, we wrote down the investment in Auralux to its fair value of $0, resulting in an impairment charge of approximately $9.6 million.
Use of Estimates – In preparing our consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”), we make estimates and assumptions that affect the amounts reported and the accompanying notes. We regularly evaluate the estimates and assumptions used and revise them as new information becomes available. Actual results may vary from those estimates.
Interim Financial Statements – The accompanying consolidated financial statements include the assets, liabilities, operating results, and cash flows of the Company and its wholly owned subsidiaries. These financial statements are prepared in accordance with U.S. GAAP for interim financial information, the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. These unaudited interim financial statements should be read in conjunction with the Company's annual consolidated financial statements and accompanying notes on Form 10-K for the year ended December 31, 2021.
2.Recent Accounting Standards
Adoption of Accounting Standard Updates
Effective January 1, 2022, we adopted Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (“ASU 2016-13”): Measurement of Credit Losses on Financial Instruments, and the subsequently issued additional guidance that modified ASU 2016-13 which was originally issued by the Financial Accounting Standards Board (“FASB”) in June 2016. The standard requires an entity to change its accounting approach in determining impairment of certain financial instruments, including trade receivables, from an “incurred loss” to a “current expected credit loss” model. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.
10

Table of Contents
Sotera Health Company
Notes to Consolidated Financial Statements
Effective January 1, 2022, we adopted ASU 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which was issued by the FASB in December 2019. The standard simplifies the accounting for income taxes and makes a number of changes meant to add or clarify guidance on accounting for income taxes. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures.

ASUs Issued But Not Yet Adopted
In October 2021, the FASB issued ASU 2021-08 - Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). The amendments in ASU 2021-08 require that an acquiring entity recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contract with Customers (“ASC Topic 606”). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC Topic 606 as if it had originated the contracts. For public business entities, these amendments are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. We are currently assessing the effect that ASU 2021-08 will have on our financial position, results of operations, and disclosures.
3.Revenue Recognition
The following table shows disaggregated net revenues from contracts with external customers by timing of revenue and by segment for the three and six months ended June 30, 2022 and 2021:
(thousands of U.S. dollars)Three Months Ended June 30, 2022
SterigenicsNordionNelson LabsConsolidated
Point in time$157,792 $46,386 $ $204,178 
Over time 4,092 58,369 62,461 
Total$157,792 $50,478 $58,369 $266,639 
(thousands of U.S. dollars)Three Months Ended June 30, 2021
SterigenicsNordionNelson LabsConsolidated
Point in time$145,182 $47,753 $ $192,935 
Over time 1,372 57,610 58,982 
Total$145,182 $49,125 $57,610 $251,917 
(thousands of U.S. dollars)Six Months Ended June 30, 2022
SterigenicsNordionNelson LabsConsolidated
Point in time$307,254 $79,671 $ $386,925 
Over time 4,809 111,659 116,468 
Total$307,254 $84,480 $111,659 $503,393 
(thousands of U.S. dollars)Six Months Ended June 30, 2021
SterigenicsNordionNelson LabsConsolidated
Point in time$276,333 $73,671 $ $350,004 
Over time 1,372 112,689 114,061 
Total$276,333 $75,043 $112,689 $464,065 
Contract Balances
As of June 30, 2022, and December 31, 2021, contract assets included in “Prepaid expenses and other current assets” on the Consolidated Balance Sheets totaled approximately $21.7 million and $15.6 million, respectively, resulting from revenue recognized over time in excess of the amount billed to the customer.
11

Table of Contents
Sotera Health Company
Notes to Consolidated Financial Statements
When we receive consideration from a customer prior to transferring goods or services under the terms of a sales contract, we record deferred revenue, which represents a contract liability. Deferred revenue totaled $6.9 million and $8.7 million at June 30, 2022 and December 31, 2021, respectively. We recognize deferred revenue after all revenue recognition criteria are met.
4.Acquisitions
Acquisition of Regulatory Compliance Associates Inc.
On November 4, 2021, we acquired Regulatory Compliance Associates Inc. (“RCA”) for approximately $30.6 million, net of $0.6 million of cash acquired. RCA is an industry leader in providing life sciences consulting focused on quality, regulatory, and technical advisory services for the pharmaceutical, medical device and combination device industries. Headquartered in Pleasant Prairie, Wisconsin, RCA will expand and further strengthen the technical consulting and expert advisory capabilities of our Nelson Labs segment.
The purchase price of RCA was allocated to the underlying assets acquired and liabilities assumed based upon management's estimated fair values at the date of acquisition. Changes to the allocation of the purchase price may occur as these measurements are completed. As of June 30, 2022, approximately $25.2 million of goodwill was recorded related to the RCA acquisition, representing the excess of the purchase price over preliminary estimated fair values of all the assets acquired and liabilities assumed. Based on our most recent estimates, we also recorded $6.4 million of finite-lived intangible assets, primarily related to customer relationships. The purchase price allocation will be finalized within a measurement period not to exceed one year from closing. We funded this acquisition using available cash. The acquisition price and the results of operations for this acquired entity are not material in relation to our consolidated financial statements.

Acquisition of Noncontrolling Interests in China Subsidiaries
On May 18, 2021, we acquired the remaining 15% and 33% noncontrolling interests associated with our two subsidiaries located in China. As a result, both entities are now 100% owned by the Company. The purchase price of the remaining equity interests was approximately $8.6 million, net of the cancellation of an $0.8 million demand note. We paid 90% of the cash consideration on the acquisition date. The remaining amounts were partially settled in post-closing payments in the third quarter of 2021; $0.2 million of the post-closing payment remain outstanding as of June 30, 2022 subject to the terms of the equity transfer agreements. As a result of the transactions, we continue to consolidate both of these subsidiaries, however, as of May 18, 2021, we no longer record noncontrolling interests in the consolidated financial statements as these subsidiaries are fully owned by the Company. The purchases were accounted for as equity transactions. As a result of these transactions, noncontrolling interests were reduced by $2.8 million reflecting the carrying value of the interest with $5.8 million of the difference charged to additional paid-in capital.
Acquisition of Mandatorily Redeemable Noncontrolling Interest - Nelson Labs Fairfield
On March 11, 2021, we completed the acquisition of the remaining 15% ownership of Nelson Labs Fairfield for $12.4 million, resulting in a gain of $1.2 million included in “Other expense (income), net” in the Consolidated Statements of Operations and Comprehensive Income (Loss) relative to the $13.6 million previously accrued. Pursuant to the terms of the acquisition, we initially acquired 85% of the equity interests of Nelson Labs Fairfield in August 2018 and were obligated to acquire the remaining 15% noncontrolling interest within three years from the date of the acquisition.
Acquisition of BioScience Laboratories, LLC
On March 8, 2021, we acquired BioScience Laboratories, LLC (“BioScience Labs”) for approximately $13.5 million, net of $0.2 million of cash acquired plus the contemporaneous repayment of BioScience Lab's outstanding debt of $1.9 million. BioScience Labs is a provider of outsourced topical antimicrobial product testing in the pharmaceutical, medical device, and consumer products industries with one location in Bozeman, Montana. BioScience Labs is included within the Nelson Labs segment.
12

Table of Contents
Sotera Health Company
Notes to Consolidated Financial Statements
The purchase price of BioScience was allocated to the underlying assets acquired and liabilities assumed based upon management's estimated fair values at the date of acquisition. Approximately $8.4 million of goodwill was recorded related to the BioScience Labs acquisition, representing the excess of the purchase price over preliminary estimated fair values of all the assets acquired and liabilities assumed. We funded this acquisition using available cash. The acquisition price and the results of operations for this acquired entity are not material in relation to our consolidated financial statements.
5.Inventories
Inventories consisted primarily of the following:
(thousands of U.S. dollars)
June 30, 2022December 31, 2021
Raw materials and supplies$33,329 $41,514 
Work-in-process484 3,919 
Finished goods5,961 8,979 
39,774 54,412 
Reserve for excess and obsolete inventory(122)(124)
Inventories, net$39,652 $54,288 
6.Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted primarily of the following:
(thousands of U.S. dollars)
June 30, 2022December 31, 2021
Prepaid taxes$27,972 $24,937